Why clinical practice guidelines matter even more in rare cancers
A recent EURACAN survey highlights a high uptake of recommendations from medical oncologists, potentially leading to improved patients’ survival
A little does not go a long way to treating cancer: updated ESMO study results cause concern about stalling progress in access to medicines
The updated Antineoplastic Medicine Survey (ANMS) dataset shows that essential therapies remain out of reach for patients in most low and lower middle-income countries despite international efforts
Three new Pan-Asian-adapted guidelines at ESMO Asia Congress
The latest tumour types covered in the ESMO PAGAs are biliary tract cancers, oncogene-addicted metastatic non-small cell lung cancer and epithelial ovarian cancer
Preventing the rise in obesity-related cancers in Asia
Long-term multisectoral preventive actions that take into account local requirements are needed
Health emergencies: let’s get prepared without leaving cancer patients behind
ESMO is advocating for secondary and tertiary care levels to be included into international agreements and WHO’s documents to respond to pandemics
WHO-ESMO collaboration sets accessible cancer care, prevention and education as priority areas of intervention
In the period 2024-2026, the technical collaboration between the United Nations agency and the Society plans a series of evidence-based activities to improve global cancer care
New Pan-Asian-adapted recommendations on gastric cancer and early breast cancer presented by ESMO
The two Pan-Asian Guideline Adaptations of parental ESMO Clinical Practice Guidelines reflect the younger age of disease occurrence and lack of some treatment data in Asia
How to improve healthcare in times of crises
Collaboration is needed to advocate for resilient healthcare systems that can navigate crises and deliver high-quality care to patients with cancer, even in the most trying circumstances
Environmental carcinogens – it’s not all about mutagens
Recent findings regarding the role of tumour promoters in cancer development should lead to a review of the mechanisms of action of existing environmental carcinogens
When your patient is the global population
Dr Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team